531 related articles for article (PubMed ID: 28283500)
1. In Vitro Interactions of Epacadostat and its Major Metabolites with Human Efflux and Uptake Transporters: Implications for Pharmacokinetics and Drug Interactions.
Zhang Q; Zhang Y; Boer J; Shi JG; Hu P; Diamond S; Yeleswaram S
Drug Metab Dispos; 2017 Jun; 45(6):612-623. PubMed ID: 28283500
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.
Ellens H; Johnson M; Lawrence SK; Watson C; Chen L; Richards-Peterson LE
Drug Metab Dispos; 2017 Jun; 45(6):646-656. PubMed ID: 28320730
[TBL] [Abstract][Full Text] [Related]
3. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
4. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
6. The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
Sheng J; Tian X; Xu G; Wu Z; Chen C; Wang L; Pan L; Huang C; Pan G
Drug Metab Dispos; 2015 Jan; 43(1):63-72. PubMed ID: 25336752
[TBL] [Abstract][Full Text] [Related]
7. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
8. Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Yu RZ; Warren MS; Watanabe T; Nichols B; Jahic M; Huang J; Burkey J; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Apr; 26(2):111-7. PubMed ID: 26959999
[TBL] [Abstract][Full Text] [Related]
9. Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator.
Choi MK; Kwon M; Ahn JH; Kim NJ; Bae MA; Song IS
Biopharm Drug Dispos; 2014 Apr; 35(3):183-94. PubMed ID: 24285344
[TBL] [Abstract][Full Text] [Related]
10. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
12. Interactions of bilastine, a new oral H₁ antihistamine, with human transporter systems.
Lucero ML; Gonzalo A; Ganza A; Leal N; Soengas I; Ioja E; Gedey S; Jahic M; Bednarczyk D
Drug Chem Toxicol; 2012 Jun; 35 Suppl 1():8-17. PubMed ID: 22616811
[TBL] [Abstract][Full Text] [Related]
13. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
14. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
15. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
19. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
20. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
Patel M; Taskar KS; Zamek-Gliszczynski MJ
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
